Last reviewed · How we verify

NCT06927024

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)

Recruiting now NA Last updated 31 December 2025
What this trial tests

NA trial testing Active taVNS in Chronic Kidney Diseases in 30 participants. Currently enrolling.

Timeline
15 October 2025
Primary endpoint
31 January 2029
31 January 2029

Quick facts

Lead sponsorNYU Langone Health
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment30
Start date15 October 2025
Primary completion31 January 2029
Estimated completion31 January 2029
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

NYU Langone Health — full company profile →

Who can join

18 and older, any sex, with Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous system (ANS) dysfunction in the chronic kidney disease (CKD) stage 3-5 setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Active taVNS

Trials testing the same drug.

Other recruiting trials for Chronic Kidney Diseases

Currently open trials in the same condition.

Other NYU Langone Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06927024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing